A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer
This include two parts, part 1 is a dose optimizing study and part 2 is a randomized, controlled study.
Metastatic Colorectal Cancer
DRUG: MAX-40279-01|DRUG: regorafenib
Disease control rate (DCR)[Part 1], Through study Part 1 completion, an average of 6 months|progress free survival(PFS)[Part 2], Through study Part 1 completion, an average of 6 months
Tmax, Time to maximum plasma concentration, Approximately 6 months|Cmax, Maximum plasma drug concentration, Approximately 6 months|AUC, Area under the time-concentration curve, Approximately 6 months|Objective response rate (ORR), 6 months (anticipated)|overall survival (OS), 24 months|Safety and tolerability assessed by incidence and severity of adverse events, 24 months
This study is a study of Max-40279-01 in patients with advanced colorectal cancer. This study include two Parts, the Part 1 will assess the safety and efficacy of the preset two dose level of Max-40279-01, and recommend a dose level of Max-40279-01 for stage 2. The part 2 is a randomized, controlled study ,and designed to compare the efficacy and safety of max-40279-01 to regorafenib or best support care(BSC) in pretreated advanced colorectal cancer.